Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Cancer organoids to model therapy response: Cancer organoids are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches can be used to predict drug responses in the clinic. They generated a live organoid biobank from patients with metastatic gastrointestinal cancer who had previously been enrolled in phase I or II clinical trials. This allowed the authors to compare organoid drug responses with how the patient actually responded in the clinic. Encouragingly, the organoids had similar molecular profiles to those of the patient tumor, reinforcing their value as a platform for drug screening and development. Science , this issue p. 920
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a living biobank of cancer PDOs from patients with metastatic and pre-treated colorectal and gastroesophageal cancer shows strong morphological, genotypic and spatiotemporal similarities between the primary tumour and the PDOs123.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“revealing strong correlations between in vitro and in vivo drug responses against cancer in the gastrointestinal tract123, bladder124, ovary125, rectum126 and pancreas127,128.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“PDOs reliably predicted treatment responses in patients, with 100% sensitivity, 93% specificity, 88% positive predictive value and 100% negative predictive value, including response to taxanes and anti-EGFR antibodies”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“These models have been particularly important in the search for anticancer compounds as they can predict patient outcomes in phase 1/2 clinical trials for gastrointestinal cancer [55].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [55]
In the citing paper
“these primary tumor clusters significantly triggered the angiogenic sprouting of HUVECs.”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [113]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
HISAT: a fast spliced aligner with low memory requirements
Kim, D., Langmead, B., & Salzberg, S. L. (2015) · Nature Methods · doi:10.1038/nmeth.3317 · Cited by 24,112
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads
Pertea, M., Pertea, G. M., Antonescu, C. M., Chang, T.-C., Mendell, J. T., & Salzberg, S. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3122 · Cited by 14,298
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Cited by
Items 901–1,000 of 1,001
Zhang, X., Xie, G., Ma, H., Ding, S., Wu, Y., Fei, Y., Cheng, Q., Huang, Y., & Wang, Y. (2023) · Biofabrication · doi:10.1088/1758-5090/acee21 · Cited by 18
Lu, H., Liu, H., Yan, R., Ma, W., Liu, H., Liu, R., Sun, Y., Ye, L., Gao, P., Jia, W., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114996 · Cited by 19
Jamieson, L. E., Harrison, D. J., & Campbell, C. J. (2018) · Journal of Biophotonics · doi:10.1002/jbio.201800201 · Cited by 16
Lee, S., Burner, D. N., Mendoza, T. R., Muldong, M. T., Arreola, C., Wu, C. N., Cacalano, N. A., Kulidjian, A., Kane, C. J., & Jamieson, C. A. M. (2020) · Journal of Visualized Experiments · doi:10.3791/60367 · Cited by 20
Stratifying nutritional restriction in cancer therapy: Next stop, personalized medicine
Krstić, J., Pieber, T. R., & Prokesch, A. (2020) · International review of cytology · doi:10.1016/bs.ircmb.2020.03.001 · Cited by 19
Dinger, T. F., Chen, O., Dittfeld, C., Hetze, L., Hüther, M., Wondrak, M., Löck, S., Eicheler, W., Breier, G., & Kunz‐Schughart, L. A. (2020) · Theranostics · doi:10.7150/thno.39893 · Cited by 17
Yamamoto, T., Miyoshi, H., Kakizaki, F., Maekawa, H., Yamaura, T., Morimoto, T., Katayama, T., Kawada, K., Sakai, Y., & Taketo, M. M. (2020) · Cancers · doi:10.3390/cancers12082010 · Cited by 16
“[19] reported in their multiple clinical trials that the positive predictability of PDSX results from clinical patients is nearly 90%; this is much higher than genomics-based patient selections.”
BackgroundHirashita, Y., Tsukamoto, Y., Kudo, Y., Kakisako, D., Kurogi, S., Hijiya, N., Nakada, C., Uchida, T., Hirashita, T., Hiratsuka, T., et al. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00590-w · Cited by 18
Kryeziu, K., Moosavi, S. H., Bergsland, C. H., Guren, M. G., Eide, P. W., Totland, M. Z., Lassen, K., Abildgaard, A., Nesbakken, A., Sveen, A., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03062-3 · Cited by 17
“Co-clinical studies have shown that PDOs can predict clinical responses to both targeted agents and chemotherapies in an observational setting [6, 7].”
BackgroundCui, Y., Xiao, R., Zhou, Y., Liu, J., Wang, Y., Yang, X., Shen, Z., Liang, B., Shen, K., Li, Y., et al. (2022) · Bio-Design and Manufacturing · doi:10.1007/s42242-022-00206-2 · Cited by 16
Evolution of precision oncology‐guided treatment paradigms
DasGupta, R., Yap, A., Yong, E. Y., & Chia, S. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1585 · Cited by 21
Efficient Establishment of Bile-Derived Organoids From Biliary Cancer Patients
Kinoshita, K., Tsukamoto, Y., Hirashita, Y., Fuchino, T., Kurogi, S., Uchida, T., Nakada, C., Matsumoto, T., Okamoto, K., Motomura, M., et al. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2023.100105 · Cited by 17
Ashley, N., Ouaret, D., & Bodmer, W. F. (2018) · The Journal of Pathology · doi:10.1002/path.5179 · Cited by 20
“Understanding how primary cultures respond to drugs can have implications for patient drug treatments [23,24].”
BackgroundColorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants
Post, J. B., Roodhart, J. M. L., & Snippert, H. J. G. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.005 · Cited by 18
Cross, W., Nowinski, S., Cresswell, G., Mossner, M., Banerjee, A., Lu, B., Williams, M., Vlachogiannis, G., Gay, L., Baker, A., et al. (2020) · bioRxiv · doi:10.1101/2020.03.26.007138 · Cited by 5
Self-citationStrelez, C., Perez, R. G., Chlystek, J. S., Cherry, C., Yoon, A. Y., Haliday, B., Shah, C. A., Ghaffarian, K., Sun, R., Jiang, H., et al. (2023) · SSRN Electronic Journal · doi:10.1101/2023.09.14.557797 · Cited by 19
Rogulska, O. Y., Havelkova, J., & Petrenko, Y. (2023) · Cryoletters · doi:10.54680/fr23210110112 · Cited by 20
Organoids as a new approach for improving pediatric cancer research
Lampis, S., Galardi, A., Paolo, V. D., & Giannatale, A. D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1414311 · Cited by 16
Functional, patient-derived 3D tri-culture models of the uterine wall in a microfluidic array
Busch, C., Hill, C. J., Paterson, K., Mellin, R., Zagnoni, M., Hapangama, D. K., & Sandison, M. E. (2024) · Human Reproduction · doi:10.1093/humrep/deae214 · Cited by 19
“Recent studies in oncology have demonstrated the superior predictive power of biopsy-derived 3D models in assessing treat-ment response prior to clinical use (Snijder et al. , 2017; Vlachogiannis et al. , 2018).”
Scholtes, M., Akbarzadeh, M., Γαλάρας, Α., Nakauma‐González, J. A., Bazrafshan, A., Solanki, V., Torenvliet, B., Beikmohammadi, L., Lozovanu, V., Romal, S., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217506 · Cited by 17
Kumar, D., Gupta, S., Gupta, V., Tanwar, R., & Chandel, A. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10893-w · Cited by 19
“…as Helicobacter pylori , facilitating the investigation of disease mechanisms and the In colorectal cancer (CRC), a study by Vlachogiannis et al. [106] involving 71 patients used CellTiter viability assay dose-response curves to evaluate organoid responses, which were then compared with clinical…”
Ma, H., Li, X., Li, J., Bu, J., Li, X., Zhang, J., Yu, S., Nie, G., Wang, H., & Feng, H. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123546 · Cited by 21
Strategies for overcoming ABC transporter-mediated multidrug resistance in colorectal cancer
de Groot, R. A., Reedijk, D., Faucher, Q., Mihaila, S. M., & Masereeuw, R. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00412.2025 · Cited by 24
Wang, Y., Zhang, L., Wang, L. Z., Cao, Y., Huang, L., Sethi, G., Chen, X., Wang, L., & Goh, B. C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02429-0 · Cited by 19
“Moreover, Vlachogiannis et al. [76] showed that PDCOs faithfully replicate patient tumors, enabling precise drug response predictions and advancing personalized medicine.”
Doerfler, R., Chen, J., Kim, C., Smith, J. D., Harris, M. K., Singh, K. B., Isett, B. R., Dadey, R., Brown, D. D., Lee, A. V., et al. (2025) · Oral Oncology · doi:10.1016/j.oraloncology.2025.107742 · Cited by 23
“PDOs are well established in cancers such as colorectal [7,8], lung [9,10], and brain [11,12], however models for HNSCC remain relatively underdeveloped.”
Organoids in drug development: from predictive models to regulatory integration
Song, X., Chen, X., Chen, Q., Wang, H., Zhang, T., Liao, M. Z., Liu, C., Yu, H., Hao, Y., Gu, G., et al. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104608 · Cited by 21
Progress and perspective of organoid technology in cancer-related translational medicine
Lin, Y., Jiang, L., He, Q., Yuan, M., & Cao, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112869 · Cited by 19
Ishida, A., Shichi, H., Fukuoka, H., Shiramizu, H., Inoshita, N., & Yamada, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.916982 · Cited by 18
“These culture models have an environment that more closely mimics various solid tumors more than 2D culture models (31).”
BackgroundTumor Organoids as a Research Tool: How to Exploit Them
Booij, T. H., Cattaneo, C. M., & Hirt, C. (2022) · Cells · doi:10.3390/cells11213440 · Cited by 17
“Colorectal and gastroesophageal cancers 55 compounds, 19 organoid types, triplicate 96 Matrigel FDA-approved CellTiterBlue (viability) [67]”
BackgroundAdine, C., Fernando, K., Ho, N. C. W., Quah, H. S., Ho, S. S. W., Wu, K. Z., Teng, K. W. W., Arcinas, C., Li, L., Ha, K., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2023.122460 · Cited by 24
Gastric cancer patient-derived organoids model for the therapeutic drug screening
Xu, J., Gong, J., Li, M., Kang, Y., Ma, J., Wang, X., Liang, X., Qi, X., Yu, B., & Yang, J. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130566 · Cited by 20
Chromatin Remodeling in Patient‐Derived Colorectal Cancer Models
Xiang, K., Wang, E., Mantyh, J. B., Rupprecht, G., Negrete, M., Sanati, G., Hsu, C., Randon, P. M., Dohlman, A. B., Kretzschmar, K., et al. (2024) · Advanced Science · doi:10.1002/advs.202303379 · Cited by 19
“PDX and PDO recapitulate drug sensitivity associated with genetic mutations (6, 7) and correlate with clinical response to chemotherapy (8, 9).”
BackgroundLin, X., Guan, T., Xu, Y., Li, Y., Lin, Y., Chen, S., Chen, Y., Wei, X., Li, D., Cui, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1337489 · Cited by 21
Chen, Y., Liu, X., Ainiwan, Y., Li, M., Pan, J., Chen, Y., Xiao, Z., Wang, Z., Xiao, X., Tang, J., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216905 · Cited by 17
Chen, D., Li, G., Luo, L., Liu, K., Chu, X., Liu, K., Lai, T., Liao, Y., Lin, X., & Chen, J. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156155 · Cited by 18
Langenberg, K. P. S., van Hooff, S. R., Koopmans, B., Strijker, J. G. M., Kholosy, W. M., Ober, K., Zwijnenburg, D. A., van der Hoek, J. J. F., Keller, K. M., Vernooij, L., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115275 · Cited by 21
Zormpas‐Petridis, K., Jerome, N. P., Blackledge, M., Carceller, F., Poon, E., Clarke, M., McErlean, C. M., Barone, G., Koers, A., Vaidya, S. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3412 · Cited by 18
“Several preclinical studies have demonstrated that quantitation of tumor fBV using SC-MRI provides a sensitive biomarker of response to vascular-targeted agents in vivo (10, 11, 13).”
BackgroundSelf-citationUse of Organoids in Medicinal Chemistry: Challenges on Ethics and Biosecurity
Rinaldi, T., & Colotti, G. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0341 · Cited by 16
“The power and the possible controversies arising from the organoids approach can be understood with the possible selection of drug treatment for individual cystic fibrosis patients on the basis of an organoid swelling assay in intestinal organoids [7], or the patient-specific responses to specific drugs in biobanked c…”
BackgroundResultBusslinger, G. A., Lissendorp, F., Franken, I. A., van Hillegersberg, R., Ruurda, J. P. H., Clevers, H. C., & de Maat, M. F. G. (2020) · Open Biology · doi:10.1098/rsob.190274 · Cited by 16
“The established PDOs recapitulated the same histopathological features as the original tumour [39].”
BackgroundResultInfluentialChang, T., Lu, C., Hsieh, Y., Wei, K., Chen, W., Tung, S.-Y., Wu, C., Chan, M. W. Y., & Chiang, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165901 · Cited by 15
“Moreover, an organoid may be used to accurately predict the patients’ responses to therapeutic drugs before the treatment [43,44].”
BackgroundLi, Y., Guo, D., Zhang, Y., Wang, L., Sun, T., Li, Z., Zhang, X., Wang, S., Chen, Y., & Wu, A. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100935 · Cited by 16
Domenici, G., Eduardo, R., Castillo‐Ecija, H., Orive, G., Carcaboso, A. M., & Brito, C. (2021) · Cancers · doi:10.3390/cancers13040879 · Cited by 15
Regan, J. L., Schumacher, D., Staudte, S., Steffen, A., Lesche, R., Toedling, J., Jourdan, T., Haybaeck, J., Mumberg, D., Henderson, D. A., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102618 · Cited by 18
Engineering stromal heterogeneity in cancer
Tang, L. J. W., Zaseela, A., Toh, C. C. M., Adine, C., Aydar, A. O., Iyer, N. G., & Fong, E. L. S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.027 · Cited by 17
A gentle introduction to understanding preclinical data for cancer pharmaco-omic modeling
Piyawajanusorn, C., Nguyen, L. C., Ghislat, G., & Ballester, P. J. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab312 · Cited by 21
Advances of Patient-Derived Organoids in Personalized Radiotherapy
Wang, Y., Li, Y., Sheng, Z., Deng, W., Yuan, H., Wang, S., & Liu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888416 · Cited by 21
“also found the PDO’s phenotypic and genotypic profiling possessed a high degree of similarity to the original patient’s tumor (6).”
BackgroundPatient-derived organoids as a model for tumor research
Wang, J., Feng, X., Li, Z., Chen, Y., & Huang, W. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.03.004 · Cited by 19
Park, J. G., Kim, S., Jang, E., Choi, S. H., Han, H., Ju, S., Kim, J. W., Min, D. S., & Jin, M. S. (2022) · Nature Communications · doi:10.1038/s41467-022-33593-2 · Cited by 15
Wang, Y., Liao, H., Zheng, T., Wang, J., Guo, D., Lü, Z., Li, Z., Chen, Y., Shen, L., Zhang, Y., et al. (2020) · PubMed · Cited by 15
Development of in vitro-grown spheroids as a 3D tumor model system for solid-state NMR spectroscopy
Damman, R., Paioni, A. L., Xenaki, K. T., Hernández, I. B., Henegouwen, P. M. P. V. B. E., & Baldus, M. (2020) · Journal of Biomolecular NMR · doi:10.1007/s10858-020-00328-8 · Cited by 15
Yang, Y., Xu, H., Ma, L., Yang, L., Yang, G., Zhang, S., Ai, X., Zhang, S., & Wang, Y. (2021) · Cancer Medicine · doi:10.1002/cam4.4336 · Cited by 17
Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer
Zhang, Y., Houchen, C. W., & Li, M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1083 · Cited by 15
Coronel, R., García-Moreno, E., Siendones, E., Barrero, M. J., Martínez–Delgado, B., Santos‐Ocaña, C., Liste, I., & Cascajo-Almenara, M. V. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1403734 · Cited by 16
“There is evidence that the response to therapy in patients correlates with effects in corresponding patient-derived organoids, such as pancreatic, ovarian, uterine, colon, gastrointestinal, brain, and cancer (Vlachogiannis et al., 2018).”
BackgroundGao, M., Ding, W., Wang, Y., Li, B., Huang, Z., Liang, N., & Wei, Z. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c01389 · Cited by 18
Gouveia, Z., Özkan, A., Giannobile, W. V., Santerre, J. P., & Wu, D. T. S. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70020 · Cited by 15
Protocol for generation and utilization of patient-derived organoids from multimodal specimen
Kang, S., Lee, M. R., Choi, W., Kong, S., & Kim, Y. (2025) · STAR Protocols · doi:10.1016/j.xpro.2025.104039 · Cited by 15
Ringnalda, F. C. A. S., van Son, G. J. F., Verweij, L. H. G., Kim, S., Amo-Addae, V., Flucke, U. E., Hiemcke‐Jiwa, L. S., Langenberg, K. P. S., Bramer, J. A. M., Heimans, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62673-2 · Cited by 20
Huang, T. H., Huang, W. T., & Bian, Q. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114222 · Cited by 14
Miloradović, D., Pavlović, D., Gazdic, M., Nikolić, S., Papić, M., Milivojević, N. N., Stojković, M., & Ljujić, B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.709183 · Cited by 17
“…in bioinformatics and liquid chromatography linked with mass spectrometry and mainly applied in the examination of induced pluripotent stem cells (iPSCs; Walther and Mann, 2010; Lindoso et al., 2019), hiPSC-derived organoids (Hale et al., 2018), or hESC-derived organoids (Nascimento et al., 2019).”
BackgroundZhao, H., Cheng, Y., Li, J., Zhou, J., Yang, H., Feng, Y., Yu, F., Khutsishvili, D., Wang, Z., Jiang, S., et al. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.05.018 · Cited by 19
“For example, Vlachogiannis et al. re-ported 100% sensitivity, 93% specificity, 88% positive predictive value, and 100% negative predictive value in predicting treatment response of metastatic gastrointestinal cancers by using patient-derived tumor organoids [5] .”
Pfohl, U., Loskutov, J., Bashir, S., Kühn, R., Herter, P., Templin, M. F., Mamlouk, S., Belanov, S., Linnebacher, M., Bürtin, F., et al. (2022) · Cancers · doi:10.3390/cancers14133252 · Cited by 13
Tan, D., An, J., Gong, M., Wang, H. H., Li, H., Han, M., Zhang, C., Zhao, Y., Xu, G., & Shi, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1043479 · Cited by 15
Yoon, C., Lu, J., Kim, B., Cho, S., Kim, J. H., Moy, R. H., Ryeom, S. W., & Yoon, S. S. (2023) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-022-05568-7 · Cited by 17
Jiang, H., Zhou, S., & Li, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1189799 · Cited by 15
Three-Dimensional Tumor Models to Study Cancer Stemness-Mediated Drug Resistance
Lamichhane, A., & Tavana, H. (2024) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-024-00798-y · Cited by 18
“For example, PDOs were used to evaluate patients’ responses and resistance to drugs [102, 104].”
BackgroundMethodIntestinal organoid modeling: bridging the gap from experimental model to clinical translation
Liu, T., Li, X., Li, H., Qin, J., Xu, H., Wen, J., Ya-qin, H., & Cao, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1334631 · Cited by 19
Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies
April-Monn, S., Kirchner, P., Detjen, K. M., Bräutigam, K., Trippel, M., Grob, T. J., Statzer, C., Maire, R., Kollár, A., Chouchane, A., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00549-2 · Cited by 20
“While our cohort was small, our results align with those of similarly sized studies of similar sizes of various cancer entities that demonstrated clinical applicability using patient-derived ex vivo models, e.g., in colorectal cancer 27,28 , pancreatic cancer 29 , and lung cancer 30 .”
BackgroundResultDong, Y., Hu, K., Zhang, J., Zhu, M., Liu, M., Yuan, Y., Sun, X., Xu, Z., Li, S., Zhu, Y., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03012-5 · Cited by 18
Zhang, Y., Liu, M., Xie, N., Wang, Z., Yu, C., Li, J., & Zhou, X. (2024) · hLife · doi:10.1016/j.hlife.2024.05.002 · Cited by 19
“In addition, orga-noids also have great potential for the development and screening of cancer drugs [19] and personalized precision treat-ment of cancer [20].”
InfluentialProgress and application of lung-on-a-chip for lung cancer
Li, L., Bo, W., Wang, G., Juan, X., Xue, H., & Zhang, H. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1378299 · Cited by 18
Wnt/β-catenin signaling is a therapeutic target in anaplastic thyroid carcinoma
Diaz, D., Bergdorf, K. N., Loberg, M. A., Phifer, C. J., Xu, G. J., Sheng, Q., Chen, S., Byrant, J. M., Tigue, M. L., Hartmann, H., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03887-0 · Cited by 18
“To evaluate Wnt inhibition as a potential therapeutic approach, we utilized our fi ne-needle aspiration-derived primary patient tumor organoid cultures, which we have been shown to closely replicate patient tumor morphology and response to therapeutics [12 – 14].”
MethodOrganoid drug profiling identifies methotrexate as a therapy for SCCOHT, a rare pediatric cancer
Kim, S., de Weert, T. A. E., Vermeulen, M. A., Ringnalda, F. C. A. S., Kester, L. A., Zsíros, J., Eising, S., Molenaar, J. J., Sanders, K., van de Wetering, M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adq1724 · Cited by 20
“With recent advances in organoid technology, tumoroids (organoids generated from tumor tissue) can be grown in vitro for a variety of carcinomas and sarcomas ( 14 – 19 ).”
Organoids in cancer therapies: a comprehensive review
Xin-Yi, J., Yan-Ran, W., Pin-Ru, D., Shi-Yi, Q., & Jiang, H. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1607488 · Cited by 19
Applications of Omics Technologies for Three-Dimensional In Vitro Disease Models
Pieters, V. M., Co, I. L., Wu, N. C., & McGuigan, A. P. (2021) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2020.0300 · Cited by 15
“37,67 For example, the groups of Valeri 68 and Tuve-son 35 treated PDOs from different patients with various chemotherapeutics and performed pharmacotranscriptomics to stratify and explain transcriptional variations to therapy response.”
Stem Cells as Therapeutic Targets in Colorectal Cancer
Zalewski, A., Snook, A. E., & Waldman, S. A. (2021) · Personalized Medicine · doi:10.2217/pme-2020-0099 · Cited by 15
Wijler, L. A., Raats, D., Elias, S. G., Dijk, F. J., Quirindongo, H., May, A. M., Furber, M., Dorresteijn, B., van Dijk, M., & Kranenburg, O. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12703 · Cited by 15
“model system to assess individual patient response to chemotherapy.(32) To evaluate whether SNCi interferes with the efficacy of chemotherapy in CRC, a panel of five patient-derived CRC organoids was used, reflecting the heterogeneous CRC patient population.”
MethodMa, S., Zhao, H., & Galan, E. A. (2021) · Advanced Biology · doi:10.1002/adbi.202100535 · Cited by 16
Cao, C., Lan, X., Shang, B., Jiang, W., Guo, L., Zheng, S., Bi, X., Zhou, A., Sun, Z., & Shou, J. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02774-8 · Cited by 14
“In a recent analysis of drug responses in patients, organoid cultures were matched with the patient response up to 90% [28].”
BackgroundInstructive Hydrogels for Primary Tumor Cell Culture: Current Status and Outlook
Jia, Y., Wei, Z., Zhang, S., Yang, B., & Li, Y. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102479 · Cited by 13
Yao, L., Zao, X.-L., Pan, X.-F., Zhang, H.-G., Wang, F.-J., & Qiao, P.-F. (2022) · Journal of Chemotherapy · doi:10.1080/1120009x.2022.2045827 · Cited by 13
“We sequenced isolated genomic DNA and performed parallel sequencing using the custom, FDA-cleared tumour profiling panel MSK IMPACT of tumoroids and their corresponding tumour biopsies to compare genome-wide copy number variations [10, 16].”
BackgroundMethodA Bayesian method to cluster single-cell RNA sequencing data using copy number alterations
Milite, S., Bergamin, R., Patruno, L., Calonaci, N., & Caravagna, G. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac143 · Cited by 16
Advances in the use of 3D colorectal cancer models for novel drug discovery
Baião, A., Dias, S., Soares, A. F., Pereira, C. L., Oliveíra, C., & Sarmento, B. F. C. C. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2056162 · Cited by 14
“Also, it can be a timeconsuming process, since it takes several weeks to form an appropriate organoid [68,88].”
BackgroundMethodZebrafish Patient‐Derived Avatars from Digestive Cancers for Anti‐cancer Therapy Screening
Costa, B. F., Estrada, M. F., Barroso, M. T., & Fior, R. (2022) · Current Protocols · doi:10.1002/cpz1.415 · Cited by 16
“…such as organoid cultures are also a highly attractive tool to be used as a screening platform for several tumor types (Driehuis et al., 2019; Vlachogiannis et al., 2018; Yang et al., 2018), but these models lack the complexity of a living organism, where dynamic interactions may occur in a…”
MethodSong, M.-H., Park, J. W., Kim, M. J., Shin, Y., Kim, S., Jeong, S., & Ku, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113260 · Cited by 14
Ryu, W., Lee, J. E., Cho, Y., Lee, G., Seo, M.-K., Lee, S. G., Hwang, J., Min, D. S., Noh, S. H., Paik, S., et al. (2019) · Cancers · doi:10.3390/cancers11040496 · Cited by 15
“of gastric tumors, particularly those resistant to chemotherapy, was further confirmed by establishing PDX derived from acquired-resistant gastric tumor [22] against FOLFOX, followed by comparing its effectiveness with that of paclitaxel commonly used as next-line therapy for the recurrent AGC patients who had receive…”
ResultBi, J., Thiel, K. W., Litman, J. M., Zhang, Y., Devor, E. J., Newtson, A. M., Schnieders, M. J., Bosquet, J. G., & Leslie, K. K. (2019) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000516 · Cited by 15
Imaging and clinical correlates with regorafenib in metastatic colorectal cancer
Khan, K. H., Cascinu, S., Cunningham, D., Kim, S., Oki, E., Seery, T. E., Shen, L., Siena, S., Tournigand, C., Turhal, N. S., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102020 · Cited by 16
“These mCRC models confirmed the association between the antiangiogenic activity of regorafenib and its clinical efficacy [39].”
BackgroundSelf-citationStamati, K., Redondo, P., Nyga, A., Neves, J. B., Tran, M. G. B., Emberton, M., Cheema, U., & Loizidou, M. (2020) · Journal of Tissue Engineering · doi:10.1177/2041731420920597 · Cited by 18
Zhao, J., Wang, R. L., Zhang, J., Zhao, Y., Qiao, S., Crouzier, T., Yan, H., & Tian, W. (2021) · Biofabrication · doi:10.1088/1758-5090/abf6bf · Cited by 17
“Valeri’s group compared anticancer drug response of ex vivo cultured patient-derived organoids (PDOs) with patient clinical trials and suggested PDOs are promising for high throughput drug screening in precision medicine [9].”
3D Organoids: An Untapped Platform for Studying Host–Microbiome Interactions in Esophageal Cancers
Flashner, S. P., Yan, K. S., & Nakagawa, H. (2021) · Microorganisms · doi:10.3390/microorganisms9112182 · Cited by 14
Modelling adult stem cells and their niche in health and disease with epithelial organoids
Szabó, L., Seubert, A. C., & Kretzschmar, K. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.09.006 · Cited by 14
Organoid culture of bladder cancer cells
Yoshida, T., Singh, A. K., Bishai, W. R., McConkey, D. J., & Bivalacqua, T. J. (2018) · Korean journal of urology · doi:10.4111/icu.2018.59.3.149 · Cited by 15
“PDOs was recently described [9], in which Vlachogiannis et al.”
MethodDong, Y., Li, J., Dai, Y., Zhang, X., Wang, T., Zhao, B., Liu, W., Chen, L., Yang, S., Du, P., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101487 · Cited by 15
Model systems to study tumor-microbiome interactions in early-onset colorectal cancer
Richter, K. M., Wrage, M., Krekeler, C., Oliveira, T. D., Conradi, L., Menck, K., & Bleckmann, A. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00198-3 · Cited by 13
“In particular, the comparison of CRC cell lines and PDOs has revealed signi fi cant differences in drug responses, indicating that PDOs are more representative models for personalized anti-cancer drug screens than traditional 2D cell cultures (Usui et al, 2016; Vlachogiannis et al, 2018).”
Alamri, A. M., Assiri, A. A., Khan, B. E. Z., & Khan, N. U. (2025) · Medical Oncology · doi:10.1007/s12032-025-03042-3 · Cited by 21
Advances in precision oncology using patient-derived organoids and functional biomaterials
Singh, H., Mijakovic̀, I., & Singh, P. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1670328 · Cited by 17
Ahmadi, N., Vidanapathirana, G. U., & Gopalan, V. (2025) · Genes · doi:10.3390/genes16101166 · Cited by 15
Advances and Challenges in Drug Screening for Cancer Therapy: A Comprehensive Review
Motohashi, S., Katsuta, E., & Ban, D. (2025) · Bioengineering · doi:10.3390/bioengineering12121315 · Cited by 20
Acar, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1733668 · Cited by 18
Lamichhane, A., Thakuri, P. S., Nejad, P. R., & Tavana, H. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211014185 · Cited by 13
“More importantly and from a disease modeling point of view, organoids that develop from patient tumor biopsies or resections recapitulate the histological and functional properties of the parental tumors,(26,27) making them a valuable tool to understand disease mechanisms and develop therapies for individual cancer pa…”
Background
Metadata
- Authors
- Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., Rata, M., Koh, D.-M., Tunariu, N., Collins, D., Hulkki-Wilson, S., Ragulan, C., Spiteri, I., Moorcraft, S. Y., Chau, I., Rao, S., Watkins, D., Fotiadis, N., Bali, M., Darvish-Damavandi, M., Lote, H., Eltahir, Z., Smyth, E. C., Begum, R., Clarke, P. A., Hahne, J. C., Dowsett, M., de Bono, J., Workman, P., Sadanandam, A., Fassan, M., Sansom, O. J., Eccles, S., Starling, N., Braconi, C., Sottoriva, A., Robinson, S. P., Cunningham, D., & Valeri, N.
- Affiliations
- Institute of Cancer Research (GB)
- Royal Marsden NHS Foundation Trust (GB)
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, UK.
- Division of Clinical Studies, The Institute of Cancer Research, London, UK.
- University of Padua (IT)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Valeri, Nicola
- ORCID
- Vlachogiannis, Georgios
- Hedayat, Somaieh
- Jamin, Yann
- Fernández-Mateos, Javier
- Khan, Khurum
- Lampis, Andrea
- Eason, Katherine
- Huntingford, Ian
- Burke, Rosemary
- Rata, Mihaela
- Koh, Dow-Mu
- Tunariu, Nina
- Collins, David
- Ragulan, Chanthirika
- Spiteri, Inmaculada
- Moorcraft, Sing Yu
- Chau, Ian
- Rao, Sheela
- Watkins, David
- Fotiadis, Nicos
- Bali, Maria
- Darvish-Damavandi, Mahnaz
- Lote, Hazel
- Eltahir, Zakaria
- Smyth, Elizabeth C.
- Begum, Ruwaida
- Clarke, Paul A.
- Hahne, Jens C.
- Workman, Paul
- Sadanandam, Anguraj
- Fassan, Matteo
- Sansom, Owen J.
- Starling, Naureen
- Braconi, Chiara
- Sottoriva, Andrea
- Robinson, Simon P.
- Cunningham, David
- Valeri, Nicola
- Venue
- Science
- Published
- 2018-02-23
- Volume
- 359
- Issue
- 6378
- Pages
- 920-926
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6112415
- OpenAlex
- W2788735115
- Cited by
- 2,096
- References
- 36
- Citations by year
- 2026: 318 · 2025: 286 · 2024: 282 · 2023: 234 · 2022: 262 · 2021: 294 · 2020: 207 · 2019: 124 · 2018: 87
- FWCI
- 66.95
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- FP7 People: Marie-Curie Actions (CIG334261)
- National Institute for Health Research (A62)
- Cancer Research UK (CEA A18052)
- European Commission (Marie Curie CIG 618154)
- European Research Council (331301)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Keywords
- patient-derived organoids, metastatic gastrointestinal cancer, colorectal cancer, gastroesophageal cancer, treatment response prediction, drug screening, tumor organoids, orthotopic xenograft, personalized medicine, biobanks, molecular profiling, anticancer agents
- MeSH terms
- Animals, Antineoplastic Agents, Gastrointestinal Neoplasms, Humans, Neoplasm Metastasis, Organoids, Phenylurea Compounds, Pyridines, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Genomics, Mice, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.